Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
Retrieved on:
Domenica, Gennaio 8, 2023
Well, Severe cognitive impairment, SAD, Autoimmune disease, Complement component 1q, Autoimmune hemolytic anemia, Disease, Growth, LN, Plasma, Medicine, Neurodegeneration, Investment, The First Half of My Life, GA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, HIV disease progression rates, Lupus nephritis, HD, Nephritis, AFL, Physician, Eye, Pivotal trial, FDA, Autoimmunity, Geographic atrophy, GBS, Anemia, Food, ALS, Continuous Progress Mathematics, Time-invariant system, Therapy, Webcast, Nerve, Hemolysis, CAD, MAD, Multifocal motor neuropathy, Cold agglutinin disease, Nerve Damage, Patient, Ophthalmology, MMN, Conference, Pharmaceutical industry, Waiha, Amyotrophic lateral sclerosis
BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.
Key Points:
- Annexon has prioritized resources and execution of late-stage development of its four flagship programs: Guillain-Barré syndrome (GBS), Huntington’s disease (HD), geographic atrophy (GA) and its first-in-kind oral small molecule, ANX1502.
- Our mission is to free the body, brain and eye from diseases driven by the classical complement cascade,” said Douglas Love, president and CEO of Annexon.
- Following an assessment of the market opportunity in wAIHA and a range of additional autoimmune indications, Annexon has determined not to advance development in wAIHA.
- A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.